Peter Heerma, Chief Commercial Officer at Travere Therapeutics ($TVTX), sold shares on the open market five times in the past year for a total of about $747,000. His most recent sale occurred on February 3, 2026. These transactions rank 5,589th out of 11,678 insiders in our database, well below the average sale amount of $8.6 million across 6 transactions per insider. He made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 3, 2026 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 7310 | $32.12 | 131,823.0000 | 89,211,813 | 5.25% | 0.01% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | A | Common Stock | 26120 | $0.00 | 139,133.0000 | 89,211,813 | 23.11% | 0.03% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | A | Employee stock option (right to buy) | 69640 | $0.00 | 69,640.0000 | 89,211,813 | 9999.99% | 0.08% |
| Dec. 24, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 4980 | $40.00 | 113,013.0000 | 102,618,560 | 4.22% | 0.00% |
| Nov. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | G | Common Stock | 1078 | $0.00 | 117,993.0000 | 102,618,560 | 0.91% | 0.00% |
| Oct. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 5591 | $35.00 | 119,071.0000 | 102,618,560 | 4.48% | 0.01% |
| Oct. 28, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 2662 | $30.00 | 124,662.0000 | 102,618,560 | 2.09% | 0.00% |
| Sept. 23, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | G | Common Stock | 891 | $0.00 | 127,324.0000 | 78,888,861 | 0.69% | 0.00% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | M | Common Stock | 4920 | $0.00 | 129,986.0000 | 78,888,861 | 3.93% | 0.01% |
| May 5, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 1771 | $21.05 | 128,215.0000 | 78,888,861 | 1.36% | 0.00% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | M | Performance-based restricted stock units | 4920 | $0.00 | 4,920.0000 | 78,888,861 | 50.00% | 0.01% |
| Feb. 10, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | M | Performance-based restricted stock units | 8000 | $0.00 | 0.0000 | 78,888,861 | 100.00% | 0.01% |
| Feb. 10, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | M | Common Stock | 8000 | $0.00 | 130,708.0000 | 78,888,861 | 6.52% | 0.01% |
| Feb. 11, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 3074 | $25.00 | 127,634.0000 | 78,888,861 | 2.35% | 0.00% |
| Feb. 12, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 2568 | $23.53 | 125,066.0000 | 78,888,861 | 2.01% | 0.00% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | A | Employee stock option (right to buy) | 58000 | $0.00 | 58,000.0000 | 78,888,861 | 9999.99% | 0.07% |
| Feb. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 5166 | $20.12 | 122,708.0000 | 78,888,861 | 4.04% | 0.01% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | A | Common Stock | 21500 | $0.00 | 127,874.0000 | 78,888,861 | 20.21% | 0.03% |
| Jan. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 1584 | $18.94 | 106,374.0000 | 78,888,861 | 1.47% | 0.00% |
| Sept. 5, 2024 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | A | Common Stock | 6750 | $0.00 | 110,149.0000 | 74,267,418 | 6.53% | 0.01% |
| Sept. 9, 2024 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 2191 | $11.52 | 107,958.0000 | 74,267,418 | 1.99% | 0.00% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | A | Employee stock option (right to buy) | 65000 | $0.00 | 65,000.0000 | 74,267,418 | 9999.99% | 0.09% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | A | Common Stock | 25000 | $0.00 | 103,698.0000 | 74,267,418 | 31.77% | 0.03% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 4195 | $8.53 | 99,503.0000 | 74,267,418 | 4.05% | 0.01% |
| Jan. 23, 2024 | Travere Therapeutics, Inc. | $TVTX | Heerma Peter | CHIEF COMMERCIAL OFFICER | S | Common Stock | 1559 | $9.07 | 78,698.0000 | 74,267,418 | 1.94% | 0.00% |